This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Molecular Diagnostics Market & Forecast (By Application, Technology, Countries, Companies & Clinical Trials) To 2017: Global Analysis

8.3 Molecular Diagnostics and Personalized Medicine: Value-Assessed Opportunities for Multiple Stakeholders Values, Needs & Expectations

8.4 Regulatory Authorities

8.5 Molecular Diagnostics as Companion Diagnostics: Value-Driven Adoption8.5.1 Behavioral Impact8.5.2 Economic Impact (Value-Based vs. Cost-Plus Pricing)

9. Molecular Diagnostics Clinical Trial Statement9.1 Detecting Respiratory Viruses in Upper and Lower Respiratory Tract Samples9.2 Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase (ALK) Translocation9.3 A Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus9.4 Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler9.5 A Two Arm, Multi-Centre Clinical Evaluation of the xTAG Respiratory Viral Panel v3 Test9.6 Collecting and Storing Tissue Samples from Patients with Rare or Cutaneous Non-Hodgkin Lymphoma9.7 Biopsies of Cancer Patients for Tumor Molecular Characterization9.8 Daptomycin versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia9.9 Collection of Tissue Samples for Cancer Research9.10 Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma9.11 Total Therapy Study XVI for Newly Diagnosed Patients with Acute Lymphoblastic Leukemia9.12 Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy9.13 Congenital Muscle Disease Study of Patient and Family Reported Medical Information9.14 Molecular and Diagnostic Classification of Non-Small Cell Lung Cancer from Fine Needle Aspirates9.15 Extending Molecular Responses with Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients in Chronic Phase9.16 CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib9.17 Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile9.18 Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients9.19 Radotinib versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients9.20 Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)

10. Molecular Diagnostics Market – Drivers10.1 Various Developments in the Molecular Diagnostics Landscape10.2 Increasing Investment in Genomics & Proteomics Research10.3 Technological Advances in Molecular Diagnostics10.4 Increasing Acceptance of the Personalized Medicine10.5 Growing Molecular Diagnostics for Food Safety

11. Molecular Diagnostics Market – Challenges11.1 Regulatory Issues11.2 Various Factors Slowing Growth of Molecular Diagnostics11.3 Reimbursement Capabilities11.4 Quality Checkpoints, Awareness & Acceptance

List of Figures:

Figure 2 1: Global – Molecular Diagnostics Market (Million US$), 2010 – 2012Figure 2 2: Global – Forecast for Molecular Diagnostics Market (Million US$), 2013 – 2017Figure 3 1: Global Molecular Diagnostics – Application Wise Market Share (Percent), 2010 – 2012Figure 3 2: Global Molecular Diagnostics – Forecast for Application Wise Market Share (Percent), 2013 – 2017Figure 3 3: Global Molecular Diagnostics – Technology Wise Market Share (Percent), 2010 – 2012Figure 3 4: Global Molecular Diagnostics – Forecast for Technology Wise Market Share (Percent), 2013 – 2017Figure 3 5: Global Molecular Diagnostics – Region Wise Market Share (Percent), 2010 – 2012Figure 3 6: Global Molecular Diagnostics – Forecast for Region Wise Market Share (Percent), 2013 – 2017

4 of 8

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs